decisionhealth Newsletters, Part B News - 2017 Issue 12 (December)
Providers bill — and earn — millions on oft-reported immunosuppressive drugs
Subscribe or sign in to view the full article.
Article Overview
This article examines Medicare claims data related to immunosuppressive drug billing under Part B, highlighting volume, payment patterns, and denial rates for the most frequently reported drug claims during 2015 and 2016. It is relevant to providers, billing teams, and coding professionals who follow drug claim utilization, reimbursement trends, and CMS reporting changes.
Why This Topic Matters
High-volume drug claims can generate significant reimbursement and denial exposure, so understanding claim trends and payer response helps billing and coding teams monitor revenue and compliance risk. The article also provides context for how Medicare reporting changes affect utilization patterns over time.
What You Will Learn
- How Medicare Part B claim activity is summarized for immunosuppressive drugs
- What the article shows about billing volume and payment trends over two years
- How denial rates are discussed in relation to high-volume drug claims
- Why changes in reporting eligibility matter for claim analysis
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle professionals
- Practice administrators
- Compliance teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com